@article{dddb90a4154d4511ba29e128a3d08a13,
title = "Accelerated development of malaria monoclonal antibodies",
abstract = "L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.1 These promising results are the first of many to usher in a potential new era of malaria prevention.",
author = "Narimane Nekkab and Penny, {Melissa A.}",
note = "Funding Information: The authors declare no competing interests. N.N. and M.P. are funded by the Bill and Melinda Gates Foundation (INV-002562 to MAP ) to model Target Product Profiles of next-generation seasonal interventions. Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = oct,
day = "18",
doi = "10.1016/j.xcrm.2022.100786",
language = "English",
volume = "3",
journal = "Cell Reports Medicine",
issn = "2666-3791",
publisher = "Cell Press",
number = "10",
}